Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 4/20 | 0.37 |
| ▸ | EGFR | P00533 | 7/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045492 | 0.90 | BTK (0.37) | BTKEGFRFGFR2 | |
| SCHEMBL20045491 | 0.84 | BTK (0.35) | BTKEGFR | |
| SCHEMBL20045475 | 0.81 | MAPK1 (0.41) | EGFRFGFR2 | |
| SCHEMBL20132849 | 0.81 | ACHE (0.42) | BTKEGFR | |
| SCHEMBL20046161 | 0.79 | KRAS (0.41) | EGFR | |
| SCHEMBL20132862 | 0.78 | KDM4E (0.38) | BTKEGFR | |
| SCHEMBL20046128 | 0.78 | KRAS (0.38) | BTK | |
| SCHEMBL20132843 | 0.77 | BTK (0.40) | BTKEGFR | |
| SCHEMBL20045414 | 0.76 | JAK3 (0.45) | BTK | |
| SCHEMBL20046111 | 0.76 | MAP3K5 (0.36) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | HSP90AA1 3840/4885HSP90AB1 3301/4885ADORA2A 3029/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HSP90AA1 3940/4885HSP90AB1 3357/4885ADORA2A 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.